The Next Frontier of Antibody-Drug Conjugate Development - Dana-Farber's Paolo Tarantino, MD, discussed how to optimize the safety of antibody drug conjugates at a session during ESMO25.
I'm just extremely excited to share and to speak at this sessions, educational session and at ESO called The Next Frontier of Antiboidra conjugates Development, and this basically will tackle all the new developments that we expect and that we're working on in the ADC field. And so personally. I will discuss about optimizing the safety of ADCs because we think of ADCs as delivering precisely chemotherapy to tumor cells, but in truth there's a lot of work left to do in order to make this chemo really precise and to avoid uh side effects for ADCs in breast cancer but across tumor types as well. And then we're gonna have talks delving into combinations because we know that ADCs combined with other treatment modalities can further enhance anti-cancer activity and just work even better with drugs such as DNA damage repair inhibitors or immunotherapy or many others. And then we have another talk by Sheri Law on predictive biomarkers for ADCs understanding. How to better select patients and we're basically in a new era of biomarkers where we're moving beyond the mini chemistry towards more quantitative techniques and even AI assisted techniques to understand which patients need which ADC at which moment and finally emerging ADC is on the horizon. There is this entire category of fancy ADCs that. For multiple chemotherapies or they deliver immunotherapy targeted drugs and other things just so much that is happening. There is over 300 new ADCs in clinical developments and so I'm really looking forward to discussing with amazing colleagues Dr. Shereen Lloyd, Tim Yap, Anthony Tolcher about the next frontiers of ADC antiboid drug conjugate development at ESO this year.
